LCN2 and metabolic dysfunction-associated steatohepatitis: Consistent with our findings, the neutralization of LCN2 has been shown to control neutrophilic inflammation in experimental disease models of psoriasis, cardiovascular disease, alcoholic steatohepatitis, and nonalcoholic steatohepatitis [49].